2023 World Conference on Lung Cancer (Posters)-EP12.01. The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment

EP12.01. The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment - PDF(Abstract)

Back to course

Pdf Summary

The study evaluated the safety and efficacy of aumolertinib, a treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC), in patients who were intolerant to osimertinib. It enrolled 9 patients who were receiving aumolertinib between April 2019 and December 2022. Adverse events were graded and the primary endpoint was the 3-month conversion success rate, defined as the proportion of patients who did not experience grade 2 hematologic toxicity or grade 3 other adverse events within 3 months of switching to aumolertinib. Secondary endpoints included progression-free survival, objective response rate, disease control rate, and overall survival.<br /><br />The results showed that the 3-month conversion success rate was 100%, indicating that all patients did not experience grade 2 hematologic toxicity or grade 3 adverse events within 3 months of starting aumolertinib. The objective response rate was 33.3% and the disease control rate was 100%. The progression-free survival and overall survival have not been reached yet. Some adverse events were observed, including grade 3 rash in 4 patients and grade 2 platelet count decrease in 5 patients. However, both platelet count decrease and rash were not observed according to the CTCAE v5.0 grading criteria.<br /><br />Based on these findings, the study concluded that aumolertinib is a safe and effective option for patients with locally advanced or metastatic EGFR-mutant NSCLC who were intolerant to osimertinib treatment. This provides an alternative treatment option for patients who experience adverse events with osimertinib. Overall, the study highlights the potential of aumolertinib in improving outcomes for patients with EGFR-mutant NSCLC.

Asset Subtitle

Qinhong Zheng

Meta Tag

Speaker Qinhong Zheng

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

aumolertinib

EGFR-mutant non-small cell lung cancer

osimertinib intolerance

safety

efficacy

adverse events

conversion success rate

progression-free survival

objective response rate

disease control rate